Oryzon Genomics SA
MAD:ORY
Oryzon Genomics SA
Additional Paid In Capital
Oryzon Genomics SA
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Oryzon Genomics SA
MAD:ORY
|
Additional Paid In Capital
€92.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
||
Grifols SA
MAD:GRF
|
Additional Paid In Capital
€910.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
||
Pharma Mar SA
MAD:PHM
|
Additional Paid In Capital
€59.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-16%
|
||
Biotechnology Assets SA
MAD:BST
|
Additional Paid In Capital
€99.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
Oryzon Genomics SA
Glance View
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
See Also
What is Oryzon Genomics SA's Additional Paid In Capital?
Additional Paid In Capital
92.4m
EUR
Based on the financial report for Dec 31, 2023, Oryzon Genomics SA's Additional Paid In Capital amounts to 92.4m EUR.
What is Oryzon Genomics SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
9%
Over the last year, the Additional Paid In Capital growth was 16%. The average annual Additional Paid In Capital growth rates for Oryzon Genomics SA have been 8% over the past three years , 9% over the past five years .